This complex disease is enmeshed with a litany of other potentially-deadly health conditions – type 2 diabetes, high cholesterol, cardiovascular disease – and is a leading cause of liver transplantation worldwide. Since most people with NASH are affected by obesity, it is also a disease shrouded in stigma. While millions of people are at risk of suffering from the potentially debilitating and deadly effects of NASH, many people aren’t aware of their disease.
There are currently no medications approved for the treatment of NASH. But with an unserved population of millions in dire need of help, many companies are now working fervently to improve detection and to develop effective treatments.
For information on Akero Therapeutics’ drug to treat NASH, please visit our section on efruxifermin.